Related Experiment Videos
Comparison of outcomes of illicit drug users and nonusers hospitalized with heart failure
Ahmad M Slim1, Hillary Thomas, Roy Parish
1Cardiology Service, San Antonio Military Medical Center, San Antonio, Texas, USA. Ahmad.slim@US.ARMY.MIL
Insights
Illicit drug use (IDU) in heart failure (HF) patients significantly shortens hospital readmission intervals and increases readmission rates. However, IDU did not impact in-hospital mortality in this study population.
Area of Science:
- Cardiology
- Clinical Medicine
- Public Health
Background:
- Long-term effects of illicit drug use (IDU) on heart failure (HF) clinical outcomes remain under-described.
- Understanding these effects is crucial for managing at-risk populations.
Purpose of the Study:
- To characterize HF patients with a history of IDU.
- To determine the impact of IDU on HF-related clinical outcomes, including mortality and readmissions.
Main Methods:
- Retrospective cohort study of HF patients from June 2003 to September 2008.
- Patients categorized into IDU and non-IDU groups based on self-report or lab results.
- Outcomes included in-hospital mortality, HF readmission rates, and time to readmission.
Main Results:
- IDU was associated with a significantly shorter interval to HF readmission (HR 3.8, p <0.0001).
- IDU independently predicted higher HF readmission rates (p = 0.0001).
- No significant association was found between IDU and in-hospital mortality (HR 0.7, p = 0.4).
Conclusions:
- Illicit drug use is linked to worse clinical outcomes in heart failure patients.
- IDU is a significant factor contributing to increased and more frequent hospital readmissions for HF.
- Further research into interventions for this patient group is warranted.
Abstract:
The long-term effects of illicit drug use (IDU) on the clinical outcome of patients with heart failure (HF) are not well described. The objective of the present study was to describe the characteristics of patients with HF who used illicit drugs and to determine the effects of IDU on the clinical outcomes such as in-hospital mortality and hospital readmission for HF. A retrospective cohort study was conducted that included all patients admitted with HF from June 2003 to September 2004 and followed up until 2008 at a university hospital serving an at-risk population. The patients were divided into 2 groups: IDU and non-IDU according to self-reported use or positive laboratory results. The outcome measures were in-hospital mortality, HF readmission rate, interval to readmission for HF, and average brain natriuretic peptide and troponin levels throughout the follow-up period. Of 646 reviewed records, 542, representing 357 patients, were included in the present analysis. Of the 357 patients, 53 patients were in the IDU group and 304 were in the non-IDU group. Kaplan-Meier log-rank analysis and Cox proportional hazard analysis showed that IDU was associated with a shorter interval to readmission for HF (hazard ratio 3.8, 95% confidence interval 2.3 to 10.7, p <0.0001) but not with in-hospital mortality (hazard ratio 0.7, 95% confidence interval 0.3 to 1.7, p = 0.4). Multiple linear regression analysis identified IDU as an independent variable for the HF readmission rate (p = 0.0001) but not for average brain natriuretic peptide or average troponin levels. In conclusion, the results of the present study have demonstrated that IDU was associated with a decreased interval to readmission for HF and greater HF readmission rates.
Related Concept Videos
Heart Failure Drugs: Diuretics
Heart Failure V: Medical Management
Heart Failure I: Introduction
Heart Failure IV: Classification and Diagnostic Evaluation
Heart Failure Drugs: Inotropic Agents
Heart Failure Drugs: β-Blockers